Physiologically Based Pharmacokinetic Modelling to Predict Pharmacokinetics of Enavogliflozin, a Sodium-Dependent Glucose Transporter 2 Inhibitor, in Humans

• Egile Nagusiak: Min-Soo Kim (Egilea), Yoo-Kyung Song (Egilea), Ji-Soo Choi (Egilea), Hye Young Ji (Egilea), Eunsuk Yang (Egilea), Joon Seok Park (Egilea), Hyung Sik Kim (Egilea), Min-Joo Kim (Egilea), In-Kyung Cho (Egilea), Suk-Jae Chung (Egilea), Yoon-Jee Chae (Egilea), Kyeong-Ryoon Lee (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2023-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Enavogliflozin is a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor approved for clinical use in South Korea. As SGLT2 inhibitors are a treatment option for patients with diabetes, enavogliflozin is expected to be prescribed in various populations. Physiologically based pharmacokinetic (P...